nach oben

Erschienen in:

01.07.2014 | Original article

Squamous cell carcinoma of the larynx with subglottic extension: is larynx preservation possible?

verfasst von: A. Levy, P. Blanchard, S. Temam, M.-M. Maison, F. Janot, H. Mirghani, F. Bidault, J. Guigay, A. Lusinchi, J. Bourhis, N. Daly-Schveitzer, Y. Tao, MD, PhD

Erschienen in: Strahlentherapie und Onkologie | Ausgabe 7/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Squamous cell carcinoma of larynx with subglottic extension (sSCC) is a rare location described to carry a poor prognosis. The aim of this study was to analyze outcomes and feasibility of larynx preservation in sSCC patients.

Patients and methods

Between 1996 and 2012, 197 patients with sSCC were treated at our institution and included in the analysis. Stage III–IV tumors accounted for 76 %. Patients received surgery (62 %), radiotherapy (RT) (18 %), or induction chemotherapy (CT) (20 %) as front-line therapy.

Results

The 5-year actuarial overall survival (OS), locoregional control (LRC), and distant control rate were 59 % (95 % CI 51–68), 83 % (95 % CI 77–89), and 88 % (95 % CI 83–93), respectively, with a median follow-up of 54.4 months. There was no difference in OS and LRC according to front-line treatments or between primary subglottic cancer and glottosupraglottic cancers with subglottic extension. In the multivariate analysis, age > 60 years and positive N stage were the only predictors for OS (HR 2, 95 % CI 1.2–3.6; HR1.9, 95 % CI 1–3.5, respectively). A lower LRC was observed for T3 patients receiving a larynx preservation protocol as compared with those receiving a front-line surgery (HR 14.1, 95 % CI 2.5–136.7; p = 0.02); however, no difference of ultimate LRC was observed according to the first therapy when including T3 patients who underwent salvage laryngectomy (p = 0.6). In patients receiving a larynx preservation protocol, the 5-year larynx-preservation rate was 55 % (95 % CI 43–68), with 36 % in T3 patients. The 5-year larynx preservation rate was 81 % (95 % CI 65–96) and 35 % (95 % CI 20–51) for patients who received RT or induction CT as a front-line treatment, respectively.

Conclusion

Outcomes of sSCC are comparable with other laryngeal cancers when managed with modern therapeutic options. Larynx-preservation protocols could be a suitable option in T1–T2 (RT or chemo-RT) and selected T3 sSCC patients (induction CT).

Ferlito A, Rinaldo A (2000) The pathology and management of subglottic cancer. Eur Arch Otorhinolaryngol 257:168–173

Aslan I, Baserer N, Yazicioglu E et al (2002) Arch. Near-total laryngectomy for laryngeal carcinomas with subglottic extension. Otolaryngol Head Neck Surg 128:177–180

Marioni G, Marchese-Ragona R, Cartei G et al (2006) Current opinion in diagnosis and treatment of laryngeal carcinoma. Cancer Treat Rev 32:504–515

Paisley S, Warde PR, O’Sullivan B et al (2002) Results of radiotherapy for primary subglottic squamous cell carcinoma. Int J Radiat Oncol Biol Phys 52:1245–1250

Shaha AR, Shah JP (1982) Carcinoma of the subglottic larynx. Am J Surg 144:456–458

Dahm JD, Sessions DG, Paniello RC, Harvey J (1998) Primary subglottic cancer. Laryngoscope 108:741–746

Forastiere AA, Goepfert H, Maor M et al (2003) Concurrent chemotherapy and radiotherapy for organ preservation in advanced laryngeal cancer. N Engl J Med 349:2091–2098

Pignon JP, Bourhis J, Domenge C et al (2000) Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: three meta-analyses of updated individual data. MACH-NC Collaborative Group. Meta-analysis of chemotherapy on head and neck cancer. Lancet 355:949–955

Lefebvre JL, Rolland F, Tesselaar M et al (2009) Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Natl Cancer Inst 101:142–152

10.

n a (1991) Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group. N Engl J Med 324:1685–1690

11.

Blanchard P, Baujat B, Holostenco V et al (2011) Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumor site. Radiother Oncol 100:33–40

12.

Hata M, Taguchi T, Koike I et al (2013) Efficacy and toxicity of (chemo)radiotherapy for primary subglottic cancer. Strahlenther Onkol 189:26–32

13.

Lefebvre JL, Andry G, Chevalier D et al (2012) Laryngeal preservation with induction chemotherapy for hypopharyngeal squamous cell carcinoma: 10-year results of EORTC trial 24891. Ann Oncol 23:2708–2714

14.

Vermorken JB, Remenar E, Herpen C van et al (2007) Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med 357:1695

15.

Lorch JH, Goloubeva O, Haddad RI et al (2011) Induction chemotherapy with cisplatin and fluorouracil alone or in combination with docetaxel in locally advanced squamous-cell cancer of the head and neck: long-term results of the TAX 324 randomised phase 3 trial. Lancet Oncol 12:153

16.

Forastiere AA, Zhang Q, Weber RS et al (2013) Long-term results of RTOG 91-11: a comparison of three nonsurgical treatment strategies to preserve the larynx in patients with locally advanced larynx cancer. J Clin Oncol 31:845–852

17.

Pointreau Y, Garaud P, Chapet S et al (2009) Randomized trial of induction chemotherapy with cisplatin and 5-fluorouracil with or without docetaxel for larynx preservation. J Natl Cancer Inst 101:498–506

18.

Lefebvre JL, Rolland F, Tesselaar M et al (2009) Phase 3 randomized trial on larynx preservation comparing sequential vs alternating chemotherapy and radiotherapy. J Natl Cancer Inst 101:142–152

19.

Posner MR, Norris CM, Wirth LJ et al (2009) Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation. Ann Oncol 20:921–927

20.

Santoro R, Turelli M, Polli G (2000) Primary carcinoma of the subglottic larynx. Eur Arch Otorhinolaryngol 257:548–551

21.

Haddad R, O’Neill A, Rabinowits G et al (2013) Induction chemotherapy followed by concurrent chemoradiotherapy (sequential chemoradiotherapy) versus concurrent chemoradiotherapy alone in locally advanced head and neck cancer (PARADIGM): a randomised phase 3 trial. Lancet Oncol 14:257–264

22.

Cohen EE, Karrison T, Kocherginsky M et al (2012) DeCIDE: a phase III randomized trial of docetaxel (D), cisplatin (P), 5-fluorouracil (F) (TPF) induction chemotherapy (IC) in patients with N2/N3 locally advanced squamous cell carcinoma of the head and neck (SCCHN). J Clin Oncol 30:35s (suppl; abstr 5500)

23.

Blanchard P, Bourhis J, Lacas B et al (2013) Taxane-cisplatin-fluorouracil as induction chemotherapy in locally advanced head and neck cancers: an individual patient data meta-analysis of the meta-analysis of chemotherapy in head and neck cancer group. J Clin Oncol 31:2854–2860

24.

Kaanders JH, Hordijk GJ, Dutch Cooperative Head and Neck Oncology Group (2002) Carcinoma of the larynx: the Dutch national guideline for diagnostics, treatment, supportive care and rehabilitation. Radiother Oncol 63:299–307

25.

Levy A, Blanchard P, Janot F et al (2014) Results of definitive radiotherapy for patients with squamous cell carcinoma of the larynx for subglottic extension. Cancer Radiother 18:1–6

26.

Park GC, Kim JS, Roh JL et al (2013) Prognostic value of metabolic tumor volume measured by 18F-FDG PET/CT in advanced-stage squamous cell carcinoma of the larynx and hypopharynx. Ann Oncol 24:208–214

27.

Wagner MM, Curé JK, Caudell JJ et al (2012) Prognostic significance of thyroid or cricoid cartilage invasion in laryngeal or hypopharyngeal cancer treated with organ preserving strategies. Radiat Oncol 7:219

28.

Beitler JJ, Muller S, Grist WJ et al (2010) Prognostic accuracy of computed tomography findings for patients with laryngeal cancer undergoing laryngectomy. J Clin Oncol 28:2318–2322

29.

Egelmeer AG, Velazquez ER, Jong JM de et al (2011) Development and validation of a nomogram for prediction of survival and local control in laryngeal carcinoma patients treated with radiotherapy alone: a cohort study based on 994 patients. Radiother Oncol 100:108–115

30.

Johansen LV, Grau C, Overgaard J (2002) Glottic carcinoma—patterns of failure and salvage treatment after curative radiotherapy in 861 consecutive patients. Radiother Oncol 63:257–267

Titel: Squamous cell carcinoma of the larynx with subglottic extension: is larynx preservation possible?
verfasst von: A. Levy
P. Blanchard
S. Temam
M.-M. Maison
F. Janot
H. Mirghani
F. Bidault
J. Guigay
A. Lusinchi
J. Bourhis
N. Daly-Schveitzer
Y. Tao, MD, PhD
Publikationsdatum: 01.07.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Strahlentherapie und Onkologie / Ausgabe 7/2014
Print ISSN: 0179-7158
Elektronische ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-014-0647-8

Neu im Fachgebiet Onkologie

Bessere Prognose mit links- statt rechtsseitigem Kolon-Ca.

06.05.2024 Kolonkarzinom Nachrichten

Menschen mit linksseitigem Kolonkarzinom leben im Mittel zweieinhalb Jahre länger als solche mit rechtsseitigem Tumor. Auch aktuell ist das Sterberisiko bei linksseitigen Tumoren US-Daten zufolge etwa um 11% geringer als bei rechtsseitigen.

Nodal-negativ nach neoadjuvanter Chemo: Axilladissektion verzichtbar?

03.05.2024 Mammakarzinom Nachrichten

Wenn bei Mammakarzinomen durch eine neoadjuvante Chemotherapie ein Downstaging von nodal-positiv zu nodal-negativ gelingt, scheint es auch ohne Axilladissektion nur selten zu axillären Rezidiven zu kommen.

Wo hapert es noch bei der Umsetzung der POMGAT-Leitlinie?

03.05.2024 DCK 2024 Kongressbericht

Seit November 2023 gibt es evidenzbasierte Empfehlungen zum perioperativen Management bei gastrointestinalen Tumoren (POMGAT) auf S3-Niveau. Vieles wird schon entsprechend der Empfehlungen durchgeführt. Wo es im Alltag noch hapert, zeigt eine Umfrage in einem Klinikverbund.

Bestrahlung nach Prostatektomie: mehr Schaden als Nutzen?

02.05.2024 Prostatakarzinom Nachrichten

Eine adjuvante Radiotherapie nach radikaler Prostata-Op. bringt den Betroffenen wahrscheinlich keinen Vorteil. Im Gegenteil: Durch die Bestrahlung steigt offenbar das Risiko für Harn- und Stuhlinkontinenz.

Live-Webinar "Chronische Unterbauch- und Viszeralschmerzen in der Praxis managen"

Springer Medizin

Squamous cell carcinoma of the larynx with subglottic extension: is larynx preservation possible?